People with type 1 diabetes have an increased likelihood of celiac disease, but screening plans differ for children and adults. Celiac disease may be found before digestive symptoms are recognized. It can also become relevant when growth, weight, nutrient status, or unexplained changes in day-to-day diabetes management raise concern.
The usual initial laboratory approach uses tissue transglutaminase IgA antibodies (tTG-IgA) and total IgA while gluten remains in the diet. Ulta Lab Tests offers the linked laboratory options to support clinician-directed evaluation. This article is educational and does not replace diabetes care, individualized insulin instructions, or medical diagnosis.
Type 1 diabetes involves immune-mediated loss of the pancreatic cells that produce insulin. Celiac disease involves an immune response to gluten that damages the small-intestinal lining in susceptible people. Shared susceptibility increases the chance of coexistence, but most people with one condition should not assume they automatically have the other.
Celiac disease may affect nutrient absorption, growth, weight, and the predictability of digestion. Yet changes in blood-sugar patterns have many possible explanations, including insulin timing, activity, illness, meal composition, and diabetes technology. Those changes can be clues, but they are not a celiac diagnostic test.
The objective is to recognize a potentially associated condition without making diabetes self-management unnecessarily complicated. A clear testing plan also avoids starting a restrictive diet on the basis of symptoms that may have another explanation.
The American Diabetes Association's Standards of Care provides separate guidance for children and adolescents and for adults. Pediatric recommendations include screening soon after type 1 diabetes diagnosis, outside critical illness, followed by repeat screening within two years and again after five years. Earlier or more frequent assessment may be appropriate with symptoms or an affected first-degree relative.
For adults, the 2026 ADA section on medical evaluation and comorbidities recommends celiac screening when gastrointestinal symptoms, signs, laboratory findings, or clinical suspicion suggest the condition. It does not establish the same fixed pediatric schedule for every adult. Clinical judgment still matters for an asymptomatic adult with a particularly relevant family history or an incomplete earlier evaluation.
| Group | General approach | What to avoid |
|---|---|---|
| Children and adolescents soon after type 1 diabetes diagnosis | Plan celiac screening with the diabetes team once outside critical illness. | Letting screening distract from urgent stabilization and essential diabetes care. |
| Children and adolescents with a prior negative screen | Use the recommended repeat-screening plan and reassess sooner when clinical findings warrant. | Waiting for the next scheduled date when new concerning symptoms appear. |
| Adults with suggestive symptoms or laboratory abnormalities | Investigate possible celiac disease with appropriate serology. | Assuming every symptom is an inevitable consequence of diabetes. |
| Adults transitioning from pediatric care | Review previous screening, dietary exposure, and any unresolved positive or borderline results. | Treating the transfer of care as the end of follow-up. |
The timing refers to a screening framework, not a guarantee that disease cannot arise between scheduled checks. Record the date and conditions of each test so the next healthcare team can interpret the history accurately.
| Finding | Potential laboratory focus | Interpretation limit |
|---|---|---|
| Persistent diarrhea, bloating, abdominal pain, or unexplained weight loss | tTG-IgA with total IgA when evaluating celiac disease | Other digestive disorders and medications may contribute. |
| Poor growth or an unexpected change in growth trajectory | Pediatric assessment, celiac serology, and selected nutritional testing | Growth needs direct measurement and clinical interpretation. |
| Unexplained anemia or recurring low iron stores | CBC and ferritin, iron, and TIBC, with investigation of the cause | Not all anemia is due to malabsorption. |
| Selected neurologic symptoms or dietary concerns | Vitamin B12 and folate testing when indicated | Deficiency is not synonymous with celiac disease or diabetes-related nerve damage. |
| Unexpected recurrent low blood sugar or changing meal-related patterns | Review diabetes management and consider associated conditions when the broader history supports them | Sensor patterns alone cannot diagnose celiac disease. |
| A first-degree relative with confirmed celiac disease | Review screening history and whether earlier reassessment is warranted | Family susceptibility does not establish active disease. |
For most people eating gluten, the first-line combination is tTG-IgA with total IgA. The immunoglobulin measurement helps determine whether the antibody class is present in an adequate amount for IgA-based interpretation. It is not itself a test for intestinal injury.
| Linked test | When it helps | Important limitation |
|---|---|---|
| tTG-IgA and total IgA | Initial celiac screening in the usual gluten-exposed setting. | A negative result can be less reliable after gluten restriction or with IgA deficiency. |
| tTG-IgG or the IgG component of deamidated gliadin peptide antibody testing | Selected IgA-deficient evaluations. | Do not substitute indiscriminate IgG testing for the usual approach in everyone. |
| Complete blood count with differential and platelets | Assessment of anemia or other blood-cell findings when clinically relevant. | It does not diagnose celiac disease or identify every deficiency. |
| Ferritin, iron, and TIBC panel | Recurring low iron stores, anemia, or suspected nutritional consequences. | Inflammation, intake, and blood loss affect interpretation. |
| Vitamin B12 and folate panel | Selected anemia, neurologic, or dietary questions. | Low levels have other causes and may require a separate evaluation. |
| Vitamin D, 25-hydroxy, total | Selected bone or nutritional concerns, especially after confirmed celiac disease. | A low result is not a celiac screen. |
NIDDK's celiac testing guidance explains why antibody class and gluten intake matter. Testing is more useful when the clinician knows the current diet and the reason for screening. Ordering a large collection of nutritional tests does not compensate for an antibody result obtained under poorly understood conditions.
A positive screen identifies a person who needs an appropriate diagnostic assessment. The antibody concentration, its relationship to the laboratory's upper limit, symptoms, age, and other findings help determine the next step. Low-level or inconsistent results may require repeat assessment or additional evaluation under specialist direction.
For U.S. adults, confirmation commonly includes upper endoscopy with duodenal biopsies. Some pediatric pathways permit diagnosis without biopsy under strict criteria, but those criteria must be applied by the appropriate specialist. A family should not infer that a positive online result meets a no-biopsy pathway by itself.
Do not independently remove gluten before the clinician has completed the confirmation plan. Doing so may reduce the diagnostic information in subsequent testing. Conversely, if celiac disease is already confirmed, do not deliberately reintroduce gluten simply to make a follow-up test positive.
Screening asks whether celiac disease may be present. Follow-up after diagnosis asks how the person is doing with treatment and whether identified problems are improving. The plan usually combines clinical review, dietary support, antibody trends, and reassessment of relevant nutritional findings.
A child needs continued growth assessment and a practical food plan that supports development. An adult may need attention to persistent anemia, weight changes, or other associated conditions. Normal follow-up antibodies do not directly prove mucosal healing, and persistent symptoms should not be dismissed solely because the antibody result improved.
When nutrient results and symptoms disagree, review food intake, replacement therapy, continuing losses, and other causes. Repeated broad testing without reviewing the diet and clinical course can create more numbers without answering the underlying question.
A gluten-free label does not tell you the carbohydrate content or nutritional quality of a food. Replacement breads, cereals, and snacks may differ substantially from the products they replace. The diabetes team and a dietitian familiar with both conditions can help adapt the existing meal and monitoring plan.
Digestive recovery and changes in meals can alter day-to-day glucose patterns, so continued observation is important. Follow the diabetes team's instructions for insulin and monitoring. Celiac treatment does not cure type 1 diabetes, eliminate the need for insulin, or guarantee a particular improvement in glycemic control.
Families also need workable school, travel, and shared-meal arrangements. The laboratory result is only one part of the burden of managing two conditions. A clear confirmed diagnosis and coordinated support help avoid unnecessary restrictions while meeting the needs of both diseases.
Celiac antibody testing alone generally does not require fasting. Other tests added to an order may have different instructions. Do not fast unnecessarily or change insulin on your own for a laboratory visit. If fasting is required for a separate measurement, obtain a specific plan from the team managing the diabetes.
Review the linked test pages for current options, pricing, age eligibility, and specimen instructions. Avoid ordering a test already included in another selected panel. Share the full reports with both the diabetes clinician and the clinician evaluating celiac disease, particularly during a transition between pediatric and adult care.
Ulta Lab Tests supports laboratory access, while coordinated clinical care provides the diagnosis and treatment plan. For the full celiac diagnostic sequence, see why testing before a gluten-free diet matters.
Celiac disease is more likely in this group and may be present without recognized digestive symptoms. Scheduled screening can identify a concern before a family notices a clear pattern. The pediatric team interprets the result with growth, gluten intake, immune status, and the clinical history, and arranges appropriate confirmation when needed.
Not automatically. Current ADA adult guidance recommends testing when symptoms, signs, laboratory abnormalities, or clinical suspicion suggest celiac disease. The pediatric schedule is more specifically timed after diabetes diagnosis. An adult's family history and previous screening still matter, so the clinician should review those details rather than simply stopping surveillance at a particular birthday.
A positive screening result requires an appropriate confirmation pathway. Age, antibody level, assay limits, symptoms, and other findings influence that pathway. Some children may qualify for specialist-directed criteria that avoid biopsy, but those criteria should not be self-applied. In U.S. adults, confirmation commonly includes endoscopy with small-intestinal biopsies.
Low total IgA can make IgA-based celiac screening less reliable. The clinician may use tTG-IgG or an appropriate IgG-based alternative. The low immunoglobulin value is not itself a celiac diagnosis. The result needs to be integrated with gluten exposure, symptoms, and any further evaluation indicated by the overall history.
It can be one reason to consider a broader assessment, but it does not establish celiac disease. Insulin timing, meals, activity, illness, and other factors frequently affect glucose patterns. Follow the diabetes team's instructions for low blood sugar and discuss persistent unexplained changes. Celiac testing is selected when the complete clinical picture supports it.
Celiac antibody testing alone generally does not require fasting, but another test in the order may have separate instructions. Confirm the requirements for the entire order. Do not change insulin or fast unnecessarily on your own. If fasting is required, obtain individualized preparation instructions from the clinician responsible for your diabetes care.
No. A gluten-free diet treats confirmed celiac disease; it does not reverse type 1 diabetes or remove the need for insulin. Dietary changes and improved digestion may affect glucose patterns, so coordination with the diabetes team remains important. A gluten-free label also does not imply that a food is low in carbohydrate.
They help assess documented deficiencies or specific clinical concerns, with repeat testing chosen according to the treatment plan. CBC, iron studies, and selected vitamin measurements may be useful, but not everyone needs the same panel. Results should be read alongside growth or weight, food intake, symptoms, and the ongoing diabetes assessment.
Ask the diabetes team when celiac testing is appropriate, how results will be confirmed, and which nutritional findings need follow-up. The digestive health laboratory-testing guide provides broader context for choosing blood and stool tests when digestive questions remain unresolved.
| Category | Test or panel | Role in the article |
|---|---|---|
| Initial celiac screening | Tissue Transglutaminase IgA Antibody — tTG-IgA | Usual first-line celiac antibody test, interpreted with gluten exposure and clinical history. |
| Initial celiac screening | Total Immunoglobulin A — Total IgA | Identifies IgA deficiency that can make IgA-based screening unreliable. |
| Conditional testing with IgA deficiency | Tissue Transglutaminase IgG Antibody — tTG-IgG | An IgG-based option when IgA deficiency changes the testing approach. |
| Conditional testing with IgA deficiency | Deamidated Gliadin Peptide IgG/IgA Antibodies | The IgG component supports selected IgA-deficient evaluations; the draft links a combined IgG/IgA product. |
| Targeted anemia assessment | Complete Blood Count with Differential and Platelets — CBC | Assesses anemia and other blood-count findings when clinically appropriate. |
| Targeted iron assessment | Ferritin, Iron, and Total Iron-Binding Capacity Panel | Evaluates recurring low iron stores, anemia, or suspected nutritional consequences. |
| Selected vitamin assessment | Vitamin B12 and Folate Panel | Investigates selected anemia, neurologic, or dietary concerns. |
| Selected vitamin and bone-health assessment | Vitamin D, 25-Hydroxy, Total | Assesses vitamin D status when indicated. A low result does not diagnose celiac disease. |
| Priority | Related Health Area | Connection to the article |
|---|---|---|
| 1 | Diabetes Health Tests | Broader diabetes testing and coordinated ongoing care. |
| 2 | Celiac Disease Tests | Celiac antibody testing and evaluation of suspected disease. |
| 3 | Vitamin and Mineral Tests | Targeted nutritional assessment and deficiency follow-up. |
Celiac Disease Testing: Why Test Before Going Gluten-Free
Celiac disease occurs more often in people with type 1 diabetes and may be present without obvious digestive symptoms. Screening and follow-up should reflect age, clinical findings, and the distinction between a positive screen and a confirmed diagnosis.
Related tests: Tissue Transglutaminase IgA Antibody Test, IgA Test, Tissue Transglutaminase IgG Antibody Test, Deamidated Gliadin Peptide IgG/IgA Antibodies, Complete Blood Count with Differential and Platelets, Ferritin, Iron, and Total Iron Binding Capacity Panel, Vitamin B12 and Folate Panel, Vitamin D, 25-Hydroxy, Total.
Ulta Lab Tests provides access to the linked laboratory options to support a clinician-directed evaluation.
Educational information only; laboratory results require clinical interpretation and do not replace individualized medical care.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
